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Abstract
Changes in gene regulation are thought to have contributed to the evolution of human development.
However, in vivo evidence for uniquely human developmental regulatory function has remained
elusive. In transgenic mice, a conserved noncoding sequence (HACNS1) that evolved extremely
rapidly in humans acted as an enhancer of gene expression that has gained a strong limb expression
domain relative to the orthologous elements from chimpanzee and rhesus macaque. This gain of
function was consistent across two developmental stages in the mouse and included the presumptive
anterior wrist and proximal thumb. In vivo analyses with synthetic enhancers, in which human-
specific substitutions were introduced into the chimpanzee enhancer sequence or reverted in the
human enhancer to the ancestral state, indicated that 13 substitutions clustered in an 81-basepair
module otherwise highly constrained among terrestrial vertebrates were sufficient to confer the
human-specific limb expression domain.
Genome sequence changes that altered the molecular machinery of development likely
facilitated the evolution of uniquely human morphological traits (1,2). Although these genetic
modifications remain largely unidentified, it has long been thought that changes in gene
expression, due to positive selection for nucleotide substitutions that modified the activity of
cis-regulatory elements, played a prominent role (3). Several cases of putatively adaptive
sequence change, including polymorphisms among human populations and apparently fixed
differences between humans and other primates, have been shown to affect in vitro promoter
or enhancer function in cell line reporter assays (4-7). However, the impact of human-specific
nucleotide substitutions on the in vivo activity of developmental regulatory elements remains
obscure.
In vivo analyses of evolutionarily conserved noncoding sequences have revealed them to be
enriched in cis-regulatory transcriptional enhancers that confer specific expression patterns
during development (8-11). Recent efforts have identified conserved noncoding sequences that
evolved rapidly on the human lineage, but it is not known if these sequences include regulatory
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elements with altered activities in humans (12-15). Here we focus on functionally
characterizing the most rapidly evolving human noncoding element yet identified, which we
termed human-accelerated conserved noncoding sequence 1 (HACNS1) (12). Although this
546 basepair element is highly constrained in all sequenced terrestrial vertebrate genomes, it
has accumulated 16 human-specific sequence changes in the ∼6 million years since the human-
chimpanzee split (Fig. 1A). We evaluated the significance of this evolutionary acceleration
using a test statistic that represents the log-likelihood, or information theoretic “surprisal,” of
observing the human sequence given the orthologous sequences from multiple terrestrial
vertebrates. Assuming HACNS1 is under functional constraint in humans, its rapid divergence
is highly unexpected based on its strong conservation in these other species (surprisal test P
value = 9.2e-12; 16). This divergence also significantly exceeds the ∼4 substitutions expected
if HACNS1 were evolving at the neutral substitution rate in humans (surprisal test P value =
1.3e-6; 16). One explanation for this dramatic acceleration is that HACNS1 has undergone
several instances of positive selection during human evolution that may have altered its
function.
To test this hypothesis, we evaluated the ability of HACNS1 and its orthologs from chimpanzee
and rhesus macaque to function as transcriptional enhancers during development using a
transgenic mouse enhancer assay in which the activity of each sequence is assessed through a
β-galactosidase (lacZ) reporter gene coupled to a minimal Hsp68 promoter (17). We initially
examined the potential enhancer activity of HACNS1 at embryonic day 11.5 (E11.5). We tested
a 1.2 kb DNA fragment encompassing HACNS1 that also contained nonconserved sequences
flanking the element, in order to include possible functional sequences near HACNS1 not
detected by conservation (Table S1). At E11.5, the human element drove strong and
reproducible reporter gene expression in the anterior limb bud, pharyngeal arches, developing
ear and eye, suggesting that HACNS1 acts as a robust enhancer during development (Figs. 1B,
C and S1). In striking contrast to the highly reproducible staining driven by the human enhancer,
which extended into the most distal region of the anterior limb bud in 5 out of 6 lacZ-positive
embryos (Figs. 1C and S1; HACNS1 embryos 1-5), the chimpanzee and rhesus orthologs failed
to drive reproducible reporter gene expression in the distal limb bud, though they did drive
moderately reproducible expression at the base of the limb (Figs. 1B, C and chimpanzee
enhancer embryos 1, 2, 6-8 and rhesus enhancer embryos 1-4, 6-8 and 10 in Fig. S1). Two of
the embryos that were transgenic for the chimpanzee ortholog and showed this pattern also
exhibited diffuse, low-level staining that extended into the anterior limb, suggesting that the
chimpanzee enhancer may possess a weak capacity to drive expression in this structure
(embryos 6 and 7 in Fig. S1). However, this infrequent pattern was in stark contrast to the
strong and highly reproducible pattern of the human enhancer. Furthermore, pharyngeal arch,
eye and ear expression was less reproducible and, where present, generally weaker in multiple
positive embryos for both nonhuman orthologs, suggesting additional sites of reduced overall
enhancer activity compared to human. To assess the HACNS1 limb expression pattern at higher
resolution, we sectioned HACNS1 transgenic embryos and found that staining in the forelimb
was restricted to the mesenchyme, forming a continuous expression domain that extended deep
into the limb bud along the antero-posterior axis at the handplate and shoulder while remaining
more anterior in between (Fig. S3). These results provide evidence that the human-specific
sequence changes in HACNS1 have resulted in a gain of function in this otherwise highly
conserved enhancer, increasing its overall robustness and producing a strong human-specific
expression domain in the anterior limb bud mesenchyme at E11.5. Since the chimpanzee and
rhesus orthologs yield similar patterns to each other and show consistent differences compared
to human, a parsimonious conclusion would be that the chimpanzee and rhesus patterns reflect
the ancestral primate state from which the human-specific pattern has evolved.
To explore the activity of HACNS1 at a more advanced stage of limb development, we
compared the expression patterns of the human, chimpanzee and rhesus enhancers in E13.5
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transgenic mouse embryos. At this stage, the human element continued to drive reproducible
reporter gene expression in the anterior developing forelimb, particularly in the shoulder and
the anterior junction of the forearm and handplate in 11 of 12 positive embryos (Figs. 2A, B,
C and embryos 1-10 and 12 in Fig. S2). In 4 of these embryos the reporter gene activity extended
into the future anterior-most digit of the forelimb (Fig. 2B). Similar expression, although with
weaker staining, was also observed in the corresponding structures in the hindlimb. Imaging
of lacZ staining in a representative HACNS1 transgenic embryo using optical projection
tomography (OPT; 18) revealed that the anterior expression evident in the whole mount
extended deep inside the limb at the forearm-handplate junction (Fig. S4). The orthologous
chimpanzee and rhesus elements failed to drive reproducible expression in the distal limbs at
this time point, though a subset of positive embryos in each case showed reporter gene
expression in the shoulder region of the limb bud, thus recapitulating the proximal tip of the
expression domain of the human enhancer (4/10 for chimpanzee, Fig. 2A and chimpanzee
enhancer embryos 2-5 in Fig. S2, and 3/12 for rhesus, Fig. 2A and rhesus enhancer embryos
1, 5 and 6 in Fig. S2). OPT imaging confirmed the absence of reproducible lacZ staining inside
the distal limb in representative embryos transgenic for the rhesus and chimpanzee enhancers
(Fig. S4). These results indicate that the human-specific enhancer activity persists across
multiple developmental stages, and suggest that the robust anterior limb expression pattern of
HACNS1 evolved from a weaker ancestral pattern that is largely confined to the base of the
limb bud, as evident in the activities of the chimpanzee and rhesus enhancers at both time
points.
We next sought to identify human-specific sequence changes responsible for the functional
change in the human enhancer. While the 16 human-specific substitutions within the 546 bp
conserved region corresponding to HACNS1 are the most striking feature of the 1.2 kb
orthologous segments we initially tested for enhancer function, these segments also included
∼650 bp of nonconserved DNA containing additional human-chimpanzee sequence
differences. To isolate the effect of the substitutions within HACNS1 on enhancer function, we
synthesized a chimeric 1.2 kb enhancer in which we transferred all 16 substitutions into the
chimpanzee sequence background (16). This “humanized” chimpanzee enhancer produced an
E11.5 expression pattern nearly identical to that of the native human enhancer, suggesting that
the human-specific sequence changes within HACNS1 are responsible for the gain of function
we observe (8/8 embryos; Figs. 3D and S1). Strikingly, these human-specific substitutions are
significantly clustered: 13 of 16 substitutions occur within an 81 basepair region of the 546-
bp conserved element (permutation test P value = 1.7e-7; 16), suggesting that this region may
be particularly relevant to the human-specific function of HACNS1 (Figs. 1A and 3A). To test
this hypothesis, we synthesized a chimeric 1.2 kb enhancer in which the 13 clustered human
substitutions were introduced into the chimpanzee sequence background (Table S2). At E11.5,
this element produced an anterior limb bud pattern highly similar to HACNS1 (6/6 positive
embryos; Figs. 3 and S1). We also performed the reciprocal experiment, synthesizing a
complementary chimeric enhancer where we replaced the 13 human-specific nucleotides in
the human enhancer sequence with their putatively ancestral orthologs from chimpanzee. This
“reverted” enhancer yielded a pattern very similar to the chimpanzee and rhesus enhancer
patterns shown in Figure 1B, with expression in the anterior limb bud greatly reduced or absent
(Figs. 3 and S1). These results confirm the robustness of the functional differences we observed
between HACNS1 and its chimpanzee and rhesus orthologs and indicate that the HACNS1
anterior limb bud pattern is largely attributable to one or more of the 13 clustered human-
specific substitutions we identified. To further dissect the functional contribution of these
substitutions, we introduced independent groups of 6 substitutions and 3 substitutions into the
chimpanzee enhancer sequence (Fig. S5). These enhancers drove variable expression in the
anterior limb bud, suggesting that at least two human-specific substitutions are required for the
gain of function in HACNS1.
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The precise molecular mechanism by which the substitutions in HACNS1 confer the human-
specific expression pattern remains to be determined. Computational analysis of predicted
transcription factor binding sites in HACNS1 and its nonhuman orthologs suggested that
multiple sites have been gained and lost in this enhancer during human evolution (Fig. S6).
Predicted human-specific binding sites for the developmental transcription factors PAX9 and
ZNF423 may contribute to HACNS1 enhancer activity, as the known expression pattern of
PAX9 in the mouse limb overlaps the human-specific limb domain of HACNS1 at E11.5 and
E13.5, and ZNF423 is expressed in the mouse handplate mesenchyme from E10.5 through
E12.5 (19-21).
Several lines of evidence suggest that the functional changes in HACNS1 are due to adaptive
evolution. The rate of human-specific accelerated evolution in HACNS1 is more than four times
the local neutral rate. Moreover, this rapid evolution is not consistent with biased gene
conversion (BGC), a neutral mechanism postulated to cause hotspots of accelerated evolution
in the genome by increasing the local fixation rate of AT to GC substitutions (22,23). Under
the neutral BGC hypothesis, one would expect an increase in the overall substitution rate across
the entire region of increased AT to GC substitution (23). An excess of AT to GC substitutions
is indeed present in HACNS1 (binomial test P value = 1.1e-4; 16), and the element lies in a
∼5-kb genomic region enriched in such substitutions (Fig. 4). However, the human-specific
substitution rate is elevated only in the narrow 81-bp region in HACNS1 described above and
is close to the local average outside of this window (Fig. 4). These data, coupled with the
human-specific functional changes in HACNS1, argue against a neutral explanation for the
rapid evolution of this element in humans.
Our results evoke the hypothesis that human-specific adaptive evolution in HACNS1 has
contributed to uniquely human aspects of digit and limb patterning. The increased dexterity of
the human hand compared to other primates is due to morphological differences that include
rotation of the thumb toward the palm and an increase in the length of the thumb compared to
the other digits (1). Human-specific changes in hindlimb morphology, such as the characteristic
inflexibility and shortened digits of the human foot, facilitated habitual bipedalism. The gain
of function in HACNS1 may have influenced the evolution of these or other human limb features
by altering the expression of nearby genes during limb development. HACNS1 is located within
an intron of CENTG2, which encodes a GTPase activating protein involved in the regulation
of endosome function, and ∼300 kb downstream of GBX2, an essential developmental
transcription factor (24,25). The potential role of CENTG2 in limb development has not been
evaluated. Although mouse Gbx2 is expressed in the developing limb, Gbx2 null mice have
not been described as showing abnormal limbs (25). However, we note that the HACNS1
expression pattern in transgenic mice may not entirely recapitulate the precise HACNS1
expression pattern in the human embryo. The accelerated evolution of HACNS1 might therefore
reflect selection for changes in structures other than, or in addition to, the limb. Elucidating
the role of HACNS1 in human morphological evolution requires further lines of evidence,
including the analysis of GBX2 and CENTG2 expression during human development and the
generation of HACNS1 targeted replacement mice. Independent of these considerations, our
study suggests that adaptive nucleotide substitution altered the function of a developmental
enhancer in humans, and illustrates a strategy that could be employed across the genome to
understand at a molecular level how human development evolved through cis-regulatory
change.
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Figure 1. Human-specific gain of function in HACNS1
A. Top: Location of HACNS1 in NCBI build 36.1 of the human genome assembly. Bottom:
Sequence alignment of HACNS1 with orthologs from other vertebrate genomes; positions
identical to human are shown in black. A quantitative plot of sequence conservation is shown
in blue above the alignment (26-28). The location of each human-specific substitution is
indicated by a vertical red line, and the depth of nonhuman evolutionary conservation at human-
substituted positions is shown by a vertical yellow line that indicates whether each sequence
is identical to chimpanzee and rhesus at that position. The cluster of 13 human–specific
substitutions in 81 basepairs is also indicated. B. Expression patterns obtained from the
HACNS1 enhancer and orthologous sequences from chimpanzee and rhesus driving expression
of a lacZ reporter gene in E11.5 mouse embryos. Arrows indicate positions in the anterior limb
bud where reproducible reporter gene expression is present or absent. A representative
HACNS1 embryo is shown at top to illustrate the relevant anatomical structures. Three embryos
resulting from independent transgene integration events are shown for each orthologous
sequence tested. C. Number of embryos transgenic for each sequence displaying the limb
expression patterns described in the text.
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Figure 2. Gain of function in HACNS1 persists at E13.5
A. Expression patterns obtained from HACNS1 and its chimpanzee ortholog in E13.5 mouse
embryos. Three embryos resulting from independent transgene integration events are shown
for each construct. Close-up views of forelimb and hindlimb expression in a representative
embryo for each construct are shown at left, and arrows indicate positions where limb
expression is present or absent. B. Dorsal view of reporter gene expression in the distal anterior
forelimb of a HACNS1 E13.5 transgenic embryo. Arrows indicate the most anterior digit. C.
Number of embryos transgenic for each construct that display the limb expression patterns
described in the text.
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Figure 3. Identification of human-specific substitutions contributing to the gain of function in
HACNS1
A. Alignment of HACNS1 with orthologous sequences from other vertebrate genomes, focused
on an 81-bp region in the element that contains 13 human-specific substitutions. The position
of each substitution is indicated by a red box above the alignment and each human-specific
nucleotide is highlighted in red. Positions in the nonhuman genomes that are identical to the
human sequence are displayed as dots. B. Expression pattern of a synthetic enhancer in which
the 13 human-specific substitutions (red box) are introduced into the orthologous 1.2 kb
chimpanzee sequence background (black bar). C. Expression pattern of a synthetic enhancer
obtained by reversion of these substitutions (black box) in the human sequence (red bar) to the
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nucleotide states in chimpanzee and rhesus. D. Number of embryos transgenic for each
synthetic enhancer that show full, partial or no expression in the limb at E11.5.
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Figure 4. Human-specific substitution rate and proportion of AT to GC substitutions in
HACNS1 and flanking genomic region
The rate of human-specific substitutions (solid red line) and the fraction of human substitutions
that are AT to GC events (solid blue line) were estimated in sliding windows across a 9 kb
interval around HACNS1. The average values of each metric for 1 Mb of genomic sequence
centered on HACNS1 are shown for reference (dashed lines). The 546 bp interval corresponding
to HACNS1 is highlighted in yellow.
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